Business
New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC
Nuvalent to present at AACR-NCI-EORTC Molecular Targets Conference Data provided further evidence that NVL-520 and NVL-655 selectively inhibited ROS1 and ALK
About this update from Nuvalent, Inc.
[{"type":"text","content":"Nuvalent to present at AACR-NCI-EORTC Molecular Targets Conference\n Data provided further evidence that NVL-520 and NVL-655 selectively inhibited ROS1 and ALK compared to TRKB, were brain-penetrant, and were active against drug-resistance mutations in preclinical models\n\n\nCAMBRIDGE, Mass., Oct. 7, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, provided new preclinical data on Thursday supporting advancement of its parallel lead programs in non-small cell lung cancer (NSCLC). NVL-520, a ROS1-selective inhibitor, and NVL-655, an ALK-selective inhibitor, were specifically designed to solve for the dual challenges of kinase resistance and selectivity which limit the activity and durability of currently available cancer therapies.\n\n \n \n \n \n \n \n\n \nThe data are available via three on-demand \"short-talk\" posters at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, which runs from Oct. 7 through Oct. 10. The presentations detail additional preclinical evidence that NVL-520 and NVL-655 1) were active against both wild-type and various known resistance variants of ROS1 or ALK, respectively; 2) were brain-penetrant with the potential to address brain metastases; and 3) selectively inhibited their targets compared to the structurally related tropomyosin receptor kinase B (TRKB), thereby minimizing the potential for off-target TRKB-related central nervous system (CNS) adverse events. The posters will also be available on the Nuvalent website.\n\"The Nuvalent discovery team operates under an ethos of thorough investigation, with the goal of ensuring that we nominate drug candidates that best embody the product profiles we have defined in close collaboration with physician-scientists,\" said Henry Pelish, Ph.D., Vice President of Biology at Nuvalent and a presenting poster author. \"This is exemplified in our approach to comprehensive in vitro characterization of target selectivity compared to the structurally similar kinase TRKB during the discovery and early development of both NVL-520 and NVL-655, which we detail here.\n\"Our physician-scientist collaborators are instrumental not only in helping us to identify the desired product characteristics...